CNS Cancers

NIH Releases Large-Scale Dataset of CT Images

August 03, 2018

Unlike most lesion medical image datasets currently available, which can detect only 1 type of lesion, DeepLesion has much diversity and contains critical radiology findings from across the body, including lung nodules, liver tumors, and enlarged lymph nodes.

Modified Polio Vaccine Looks Promising in Early Glioblastoma Trial

By June 26, 2018

PVSRIPO is a prototypic oncolytic recombinant polio virus vaccine that recognizes the poliovirus receptor CD155, which is widely expressed in neoplastic cells of solid tumors.

Afinitor Disperz Approved to Treat TSC-Associated Partial-Onset Seizures

By April 11, 2018

The approval was based on the Phase 3, randomized, double-blind, placebo-controlled EXIST-3 (EXamining everolimus In a Study of TSC) study which evaluated adjunctive Afinitor Disperz (low exposure: 3-7ng/mL; high exposure: 9-15ng/mL) in patients with treatment-resistant TSC-associated partial-onset seizures, defined as inadequate control of partial-onset seizures despite use of ≥2 sequential regimens of single or combined anti-epileptic drugs.

FDA Fast Tracks Pedmark for Prevention of Cisplatin-Induced Ototoxicity

By March 21, 2018

The Clinical Oncology Group Protocol ACCL0431 trial enrolled 125 pediatric patients newly diagnosed with a germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other malignancy.

Selumetinib Gets Orphan Drug Designation for Neurofibromatosis Type 1

February 15, 2018

NF1 has no known cure and is associated with highly-variable symptoms

Entrectinib Gains Orphan Drug Status for NTRK Fusion(+) Tumors

By July 10, 2017

Currently, entrectinib is being evaluated in the global, multicenter, open-label, potentially registration-enabling Phase 2 STARTRK-2 trial (Studies of Tumor Alterations Responsive to Targeting Receptor Kinases)

First Fluorescing Agent Approved for Use with Gliomas

By June 08, 2017

The approval was supported by three prospective studies that showed aminolevulinic acid-induced fluorescence was highly predictive for visualizing malignant tissue as verified by histopathology of biopsied fluorescent tissue.

Vaccine-Chemo Combo Promising for Glioblastoma

April 17, 2017

Four of the 11 patients in this study survived for more than 5 years after vaccine/chemotherapy treatment.

Wearable Device Plus Temozolomide Tx May Improve Survival in Glioblastoma

April 03, 2017

The researchers found that the median progression-free survival was 6.7 and 4.0 months for patients treated with TTFields/TMZ and TMZ alone, respectively.

Massage Improves Pain, Lymphedema in Female CA Patients

March 10, 2017

The researchers found that all participants reported a positive experience with aromatherapy massage.

CDC: Cancer Screening 'Considerably' Below Targets

March 07, 2017

The researchers found that screening test use remained considerably below HP2020 targets for selected cancer screening tests.

Combination Biologic Granted Breakthrough Status for High Grade Glioma

By February 23, 2017

The Breakthrough Therapy designation was supported by safety, efficacy (durable, complete or partial tumor shrinkage) and patient survival data from three Phase 1 studies involving 126 patients with recurrent brain cancer.

Selumetinib Active in Children With Neurofibromatosis Type 1

December 29, 2016

Patients were able to receive selumetinib on long-term basis; maximum tolerated dose 25 mg/m

Antifungal-Chemotherapy Drug Interaction Update

By September 13, 2016

The Food and Drug Administration (FDA) has approved an update to the labeling for Noxafil (posaconazole; Merck) regarding an interaction with vincristine.

Amerigen Approved for Generic Temodar

By August 18, 2016

Amerigen announced that the FDA has granted final approval to the Abbreviated New Drug Application (ANDA) for Temozolomide Capsules, the generic version of Merck's Temodar.

FDA: Beware of Counterfeit Cancer Drug

By May 13, 2016

The Food and Drug Administration (FDA) is informing that a counterfeit version of BiCNU (carmustine for injection; Heritage) 100mg has been identified in some foreign countries.

First-in-Class ChemoTx Granted Orphan Drug Status for Pediatric Brain CA

By March 15, 2016

The Food and Drug Administration (FDA) has granted Orphan Drug designation for VAL-083 (DelMar) in the treatment of medulloblastoma, the most common malignant pediatric brain cancer.

Cancer Deaths Declining by 1.5% a Year in the U.S.

March 10, 2016

Overall rates of cancer and cancer mortality in the United States continue to decline, according to the Annual Report to the Nation on the Status of Cancer.

Does Having a Respiratory Condition Lower the Risk of Glioma?

February 08, 2016

Patients with respiratory allergies, asthma, and eczema may be less likely to develop a glioma, according to a study published in the February issue of Cancer Epidemiology, Biomarkers & Prevention.

Possible New Tx for Pediatric Brain Tumors

February 01, 2016

An open-label, phase 2 trial showed acceptable toxicity and survival rates for the use of proton radiotherapy in children with medulloblastoma.

Novel Tx Granted Orphan Drug Status for Aggressive Brain Cancer

By November 19, 2015

The FDA has granted Orphan Drug designation to marizomib (Triphase Accelerator) for the treatment of malignant glioma, an aggressive form of brain cancer with a significant unmet need due to its poor prognosis.

Optune Device Gains Expanded Indication

October 07, 2015

The U.S. Food and Drug Administration on Monday expanded its approval for the Optune device to include newly diagnosed glioblastoma multiforme.

Overweight, Obesity May Be Tied to Brain Tumor Risk

By September 17, 2015

A new article published in Neurology suggests that being overweight or obese may be linked to an increased risk of developing meningioma, a type of brain tumor.

Chemoradiation for Glioblastoma Takes Toll on Brain

September 17, 2015

Structural changes include reduced gray matter volume and ventricular enlargement

Cracked Child-Resistant Bottle Caps Prompt Oncology Drug Recall

By August 18, 2015

Merck announced a voluntary recall of Temodar (temozolomide) and its generic Temozolomide (Sandoz) capsules due to the potential for the bottle caps to be cracked.

Amneal Expands Generic Line With 4 New Products

By July 17, 2015

Amneal announced the recent launch of four new products: Tobramycin Inhalation Solution, Memantine HCl Immediate Release Tablets, Temozolomide Capsules, and Divalproex Sodium Extended Release Tablets.

Toca 511 and Toca FC Fast Tracked for Recurrent High Grade Glioma

By July 09, 2015

The Food and Drug Administration (FDA) has granted Fast Track status to Toca 511 and Toca FC for the treatment of recurrent high grade glioma, which includes glioblastoma and anaplastic astrocytoma.

Genome-Wide Data Can Classify Gliomas Into Subtypes

June 11, 2015

Two studies show distinct molecular classes of gliomas based on genomic alterations

Anticoagulation Tx in Patients With Brain Metastases: Safety Assessed in Study

June 04, 2015

Therapeutic anticoagulation is safe for treating venous thromboembolism in patients with cancer that has metastasized to the brain, according to new research.

Risks of Whole Brain Radiation Tx May Outweigh Benefits

June 01, 2015

Targeted radiation in the treatment of brain metastases leads to less cognitive damage than radiation for the entire brain, while survival is similar, researchers reported at the annual meeting of the American Society of Clinical Oncology. In a second study, researchers report that early trials of a new form of gene therapy may give hope to patients battling glioblastoma.